Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by OttawaPeteron Jan 20, 2023 2:01pm
102 Views
Post# 35236096

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:2-million-dollar fee

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:2-million-dollar fee

G1945V wrote:
OttawaPeter wrote:

ronrydell wrote: I agree....we could have $50 ADR's several years down the road if the glioblastoma trials worked and we got FDA approval....For us heavy share Bioasis holders...we would at least get our money back so both Medatech shareholders and Bioasis should vote yes (IMHO) and they hope and wait.

Bioasis will fold shortly staying on it's own, the requested for more debentures  to give us warrants is long gone.

 

...in several years being key phrase. It is a bunch of bs and highly unlikely given how Midatech is driving themselves into ground

bioasis will not fold if handled by a small competent management team who isn't busy working on their other company, raising for other companies. DR had total conflict of interest & total hypocrit. 



OttawaP,  I assume that you are in the vote  "NO" column based on your last statement.

Have you read fuzzyjr's post in regards to a "NO" vote? It seems pretty clear-cut. Do you agree?  


"Consequences of a "no" vote: from IR"


https://stockhouse.com/companies/bullboard/v.bti/bioasis-technologies-inc?postid=35230529


G1945V


 

Now I remember why I chose not to post on here prior to 2018...

of course I read it. Just don't believe the spin DR & other management are spewing. Someone write there is "added transparency" - ha! What a load...

Correct - firm NO vote. there ARE several other options bioasis should be exploring or should have explored - some non-dilutive! Not my job the educate this lot.

p.s. Thanks @Boomskid - your latest post thoughtful &'considered & is probably right. I dunno- but still voting no. 

<< Previous
Bullboard Posts
Next >>